Tonix Pharmaceuticals Holding Corp. cash flow to debt ratio of -7.63K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tonix Pharmaceuticals Holding Corp.'s free cash flow has decreased 69.08% from $-61.05M last year to $-103.21M, signaling decreasing performance

Tonix Pharmaceuticals Holding Corp.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Tonix Pharmaceuticals Holding Corp.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.01 today, signaling strengthened financials

Tonix Pharmaceuticals Holding Corp. has a net cash position, so leverage is healthy.

Tonix Pharmaceuticals Holding Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

Tonix Pharmaceuticals Holding Corp.'s profit margin has increased (-57.41%) in the last year from -1.29K% to -548.64%, signaling increasing performance

Tonix Pharmaceuticals Holding Corp.'s short-term assets of $228.88M exceed its short-term liabilities of $30.84M

Tonix Pharmaceuticals Holding Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tonix Pharmaceuticals Holding Corp.'s return on equity of -68.99%, is lower than 15.00%, indicating bad performance

Tonix Pharmaceuticals Holding Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tonix Pharmaceuticals Holding Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings

Tonix Pharmaceuticals Holding Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Tonix Pharmaceuticals Holding Corp. has negative free cash flow, indicating cash burn

Tonix Pharmaceuticals Holding Corp.'s yearly earnings has increased -4.63% since last year from $-130.04M to $-124.02M, signaling increasing performance

Tonix Pharmaceuticals Holding Corp.'s yearly revenue has increased 29.85% since last year from $10.09M to $13.11M, signaling increasing performance

ROIC -74.00% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Tonix Pharmaceuticals Holding Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

Tonix Pharmaceuticals Holding Corp. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Tonix Pharmaceuticals Holding Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Tonix Pharmaceuticals Holding Corp. has insufficient data to evaluate this check.

Tonix Pharmaceuticals Holding Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tonix Pharmaceuticals Holding Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tonix Pharmaceuticals Holding Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tonix Pharmaceuticals Holding Corp. has insufficient data to evaluate this check.

Tonix Pharmaceuticals Holding Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tonix Pharmaceuticals Holding Corp. has a price-to-book ratio of 0.94x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Tonix Pharmaceuticals Holding Corp. has a price-to-sales ratio of 7.20x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue